Skip to content

Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Prostate Cancer

To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL

null

Conditions de participation

  • Sexe:

    MALE

  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

* Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
* ECOG 0-1
* Charlson Comorbidity Index ≤ 4
* Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.

Exclusion - none

Lieu de l'étude

CHUQ
CHUQ
Québec, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Josee Allard

[email protected]
Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de Montréal
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Mom Phat

[email protected]
514-890-8000
Étude parrainée par
Centre hospitalier de l'Université de Montréal (CHUM)
Participants recherchés
Plus d'informations
ID de l'étude: NCT04100174